Pacific Biosciences of California, Inc. PACB
2.12 USD -0.12 (-5.35%)
Nov 11, 2026, 2:34 PM EST
2.07 Day range 2.35
1.07 52-week range 3.44
- YTD
- +13.37%
- 1 year
- +13.98%
News
benzinga.com UBS Maintains Neutral on Pacific Biosciences, Lowers Price Target to $2.7 UBS analyst Doug Schenkel maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target from $3.05 to $2.7.
seekingalpha.com Pacific Biosciences Q3: Another Revenue Guidance Cut Pacific Biosciences reported mixed Q3 results, with revenues beating reduced estimates but gross margins falling. Despite continually declining street revenue estimates, management was disappointed…
benzinga.com Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $2 Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1.25 to $2.
benzinga.com Piper Sandler Reiterates Neutral on Pacific Biosciences, Raises Price Target to $3 Piper Sandler analyst David Westenberg reiterates Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $2 to $3.
seekingalpha.com Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript
zacks.com Pacific Biosciences of California (PACB) Reports Q3 Loss, Beats Revenue Estimates Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.12 per share a year…
marketbeat.com What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call Pacific Biosciences of California NASDAQ: PACB reported 6% revenue growth for the third quarter of 2026 as customers adopted its SPRQ-Nx sequencing chemistry, though consumables revenue declined from…
benzinga.com Pacific Biosciences Q3 2026 Earnings Call Transcript Pacific Biosciences (NASDAQ:PACB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…- benzinga.com Pacific Biosciences Narrows FY2026 Sales Guidance from $155.000M-$165.000M to $155.000M-$160.000M vs $158.871M Est Pacific Biosciences (NASDAQ:PACB) narrows FY2026 sales outlook from $155.000 million-$165.000 million to $155.000 million-$160.000 million vs $158.871 million estimate.
globenewswire.com PacBio Announces Third Quarter 2026 Financial Results MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed; Dow gained ~100 points. Vertiv jumped 13.3% on strong results and raised guidance; Ultralife soared 145.8% on buyout news.
benzinga.com PacBio And Verily Health Announce Multi-Year Strategic Collaboration To Integrate PacBio HiFi Sequencing With Verily Health’s Governed Data And AI Platform PacBio (NASDAQ:PACB), developer of the world’s most advanced sequencing technologies, and Verily Health Inc., a healthcare data intelligence company, announced today a multi-year strategic…
benzinga.com Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday U.S. stocks rose; Apogee surged 10% on strong results and raised guidance, while Option Care, Ginkgo, PacBio and others posted double-digit gains.- benzinga.com PacBio, TychoBio Collaborate Over Generation Of RNA Data To Train Models For RNA Therapy Design PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and TychoBio, an AI drug discovery company, today announced a collaboration to generate full-length RNA data…
benzinga.com Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as Progress Software fell after results; Corteva, NFT, Vivakor and other stocks also dropped in premarket trading.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday's regular session. Tenon Medical (NASDAQ:TNON) stock increased by 47.25% to $4.02. The market value of…
benzinga.com Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
benzinga.com UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35 UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.
benzinga.com Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.- benzinga.com Pacific Biosciences Of California Approves Restructuring Plan To Align With Strategic Initiatives; Restructuring To Reduce Workforce By About 8%; Expects $30M-$40M Annualized Operating Expense Reduction By End Of 2027; Estimates $2M Pre-Tax Charges For Reduction In Force On July 30, 2026, the Board of Directors (the "Board") of the Company approved a restructuring plan to continue to better align the Company’s organizational structure and resources with its strategic
- benzinga.com Pacific Biosciences Lowers FY2026 Sales Guidance from $165.000M-$175.000M to $155.000M-$165.000M vs $166.790M Est Pacific Biosciences (NASDAQ:PACB) lowers FY2026 sales outlook from $165.000 million-$175.000 million to $155.000 million-$165.000 million vs $166.790 million estimate.
benzinga.com Pacific Biosciences of California Appoints Mark Van Oene As President, CEO, Effective Immediately, Succeeding Christian Henry Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions, today announced that its Board of Directors has appointed…
benzinga.com Pacific Biosciences Q2 Adj. EPS $(0.14) Misses $(0.13) Estimate, Sales $39.007M Miss $40.067M Estimate Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 7.69 percent decrease over losses of…
benzinga.com Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,502 shares of Kodiak AI- benzinga.com Blank Bio Closes $7.2M Seed Financing And Strategic Collaboration With Pacific Biosciences Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomesBlank Bio, an applied AI research lab training foundation models for…
benzinga.com Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5 Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1 to $1.5.- benzinga.com Pacific Biosciences Sees FY2026 Sales $165.000M-$175.000M vs $173.371M Est Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371 million analyst estimate.
- benzinga.com Pacific Biosciences Q1 Adj. EPS $(0.12) Beats $(0.14) Estimate, Sales $37.178M Miss $39.986M Estimate Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 7.69 percent. This is a 20 percent increase over losses of…
- benzinga.com PacBio And PerkinElmer Subsidiary Covaris Announce That A Joint Workflow Has Been Developed For Robust HiFi Sequencing Of Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue Samples The protocol will be formally presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting. This solution integrates Covaris' truXTRA FFPE extraction technology with…
- benzinga.com Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5 Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to Underweight and lowers the price target from $2 to $1.5.
benzinga.com Insights into Pacific Biosciences Q4 Earnings - benzinga.com Pacific Biosciences Q4 Adj. EPS $(0.12) Beats $(0.15) Estimate, Sales $44.645M Beat $42.530M Estimate Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 18.37 percent. This is a 40 percent increase over losses of…
benzinga.com Earnings Scheduled For February 12, 2026 
benzinga.com Uncovering Potential: Pacific Biosciences's Earnings Preview 
benzinga.com PacBio Completes Sale Of Select IP And Other Assets To Illumina For $48.1M In Net Cash PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to…- benzinga.com PacBio Plans Strategic Collaboration With n-Lorem Foundation And EspeRare To Advance Long-Read Whole-Genome Sequencing For Individualized ASO Therapies In Ultra-Rare Genetic Diseases PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we…
- benzinga.com PacBio To Employ PacBio HiFi Whole-Genome Sequencing To Probe Sudden Unexplained Death In Childhood PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that a UW Medicine and Seattle Children's research effort led by Danny Miller, MD, PhD, and…
- benzinga.com PacBio Reports Q4 2025 Revenue Of ~$44.6M; FY25 Revenue Of ~$160M PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6…
benzinga.com Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the year of the genomic revolution.- benzinga.com Barclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2 Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and raises the price target from $1.5 to $2.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2 Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $1.5 to $2.
- benzinga.com Stephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2 Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overweight and raises the price target from $1.8 to $2.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Pacific Biosciences Q3 Adj. EPS $(0.12) Beats $(0.15) Estimate, Sales $38.441M Miss $40.210M Estimate Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 22.58 percent. This is a 29.41 percent increase over losses of…
- benzinga.com PacBio Announces The Publication Of A New Preprint From The HiFi Solves EMEA Consortium, "HiFi Sequencing Accurately Identifies Clinically Relevant Variants In Paralogous Genes" PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today announced the publication of a new preprint from the HiFi Solves EMEA Consortium, "HiFi sequencing…
benzinga.com Earnings Scheduled For November 5, 2025